Jul 22, 2024 | Advocacy, Diabetes Business, Featured, Research News, Technology Updates
Dexcom G7 & Geofencing: Travel Alert If you are a Dexcom G7 user or using MDI with connection to phone app, PLEASE READ: you are planning travel shortly away from your home country, and you use open-source DIY app or MDI or Mobi or will use O5 with G7 Dexcom G7 is...
Jul 15, 2024 | Advocacy, Diabetes Business, Featured, Podcasts, Research News, Technology Updates, Videos
Novo’s once-weekly insulin rejected by FDA by Kristin Jensen for BioPharmaDive.com, 11 July 2024. Novo is one of the world’s premier manufacturers, along with Indianapolis-based Eli Lilly. Both have been working for years to offer patients a more convenient option...
Jul 8, 2024 | Advocacy, Diabetes Business, Featured, Videos
A Warning about Counterfeit Mounjaro, Ozempic, and Other Diabetes Medications by Dr. Steven Edelman for TCOYD, 1 July, 2024. Counterfeit Medications Are a Global Problem: Since the beginning of time, disreputable individuals have tried to make a profit off of...
May 28, 2024 | Advocacy, Diabetes Business, Featured, Foods, Podcasts, Research News, Technology Updates
FDA approves hybrid closed-loop insulin delivery app from CamDiab by Sean Whooley for DrugDelieveryBusiness.com, 24 May 2024. CamDiab announced today that the FDA granted authorization for its CamAPS FX advanced adaptive closed-loop artificial pancreas app. CamAPS FX,...
May 20, 2024 | Advocacy, Diabetes Business, Featured, LOOPing, Podcasts, Research News, Technology Updates, Videos
Meet the newest insulin pump: all about “twiist” with Sequel CEO Alan Lotvin by Stacey Simms for Diabetes-Connections.com, 16 April 2024. This week, the newest pump coming to the market is called the twiist. It’s a very different shape – circular with a top half that...
Apr 29, 2024 | Advocacy, Diabetes Business, Featured, Foods, Research News
Introducing Cadisegliatin, a New Drug in the Type 1 Diabetes Pipeline by Ross Wollen for DiabetesDaily.com, 26 April 2024. Cadisegliatin, an investigative therapy currently entering phase 3 trials, could be the next important drug, after insulin, indicated for Type 1...